Fibrinogen Concentrate as Initial Treatment for Postpartum Haemorrhage - A Randomised Clinically Controlled Trial
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 249
- 试验地点
- 4
- 主要终点
- Incidense of transfusion with allogenic blood products
研究概览
简要总结
Severe maternal bleeding is a serious complication of birth and causes 125.000 deaths worldwide each year. The investigators aim to investigate if early treatment with fibrinogen concentrate versus saline can reduce the incidence of blood transfusion in women with postpartum haemorrhage.
A low level of fibrinogen has been associated with increased blood loss and transfusion requirements in different clinical settings including obstetrical bleeding. Early up-front treatment with fibrinogen may reduce incidence of transfusion by securing optimal haemostatic capacity in women with postpartum haemorrhage.
The investigators plan to enrol 245 patients on four hospitals in the Capital Region of Denmark during a two year period.
As safety measure the investigators plan to use TEG®/Functional Fibrinogen/Rapid-TEG as haemostatic monitoring of all participants during the trial: Baseline test is taken at inclusion before administration of fibrinogen concentrate/placebo. Further tests are taken immediately after intervention, 4 hours and 24 hours after. Baseline test is blinded to the providers of treatment - the rest is clinically available.
详细描述
Experimental design Design: We plan to conduct a randomised double-blinded clinically controlled trial: The participants are assigned to either 1) placebo (100 ml of isotonic saline) i.v. or 2) the intervention drug: 2 g of fibrinogen concentrate (Haemocomplettan, CSL Behring) i.v. We intend to use a fixed dose for all patients randomized to the intervention group without prior measurement of the fibrinogen level. This strategy is primarily based on the clinical urgency since the treatment is required to be administered as early as possible.
Materials and duration of study Patients will be included during a two year period at the four largest hospitals in the Capital Region: Rigshospitalet, Hvidovre, Hillerød and Herlev if they fulfil the following eligibility criteria Plan of trial execution In order to secure the ethical aspect "Time for reflection" we will provide all pregnant women who appear in the centres during the trial period with written information on the trial during their midwife evaluation. Only 1,75% of these women are estimated to meet the inclusion criteria postpartum.
Intensive haemostatic monitoring Haemostatic blood samples including thrombelastography (TEG®), functional fibrinogen-assay for TEG®, Rapid-TEG, fibrinogen-level, d-Dimer, INR (international normalized ratio), platelet count and Antithrombin III will be drawn 15 minutes after the intervention is given, 4 hours and 24 hours later. The samples taken after the intervention are fully available for evaluation by the clinicians responsible for the patient. The patient will be observed with blood pressure, pulseoximetry, ECG and possible side effects or re-bleeding will be evaluated.
Follow up The patients will remain hospitalized for a minimum of 24 hours. We will contact all participants by phone six weeks after the intervention. Upon discharge from the hospital, all included patients receive information-material addressing possible late side effects and a contact number.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Informed consent from participant.
- •Women who develop PPH defined as bleeding from uterus and/or the birth canal within 24 hours postpartum.
- •Age ≥ 18 years.
- •If vaginal birth: indication of one of the following procedures at the operation theatre with anaesthetic assistance: a) Estimated blood loss ≥ 500 ml and indication of manual removal of placenta or b) Indication of manual exploration of the uterus due to continuous bleeding after the birth of placenta.
- •If birth by Caesarean section: A perioperative blood loss ≥ 1000 ml.
排除标准
- •Patients with known inherited deficiencies of coagulation.
- •Patients in anti-thrombotic treatment prepartum due to increased risk of thrombosis.
- •Patients with a pre-pregnancy weight <45 kg.
- •Patients who refuse to receive blood transfusion.
研究组 & 干预措施
Fibrinogen Concentrate
干预措施: Fibrinogen Concentrate (Drug)
Placebo
Isotonic Saline
干预措施: Isotonic Saline (Drug)
结局指标
主要结局
Incidense of transfusion with allogenic blood products
时间窗: During hospital stay or until 6 weeks postintervention
次要结局
- Severe Postpartum Haemorrhage (PPH)(During hospital stay or until 6 weeks postintervention)
- Estimated blood loss(During hospital stay During hospital stay or until 6 weeks postintervention)
- Total amount of blood transfused(During hospital stay During hospital stay or until 6 weeks postintervention)
- The development of re-bleeding(Untill follow-up 6 weeks postintervention)
- Hemoglobin level below 3,6 mmol/L(During hospital stay or until 6 weeks postintervention)
- Side-effects including thromboembolic complications(Untill 6 weeks postintervention)
研究者
Anne Juul Wikkelsø
MD
Copenhagen University Hospital at Herlev